Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18619099 | Akkermansia Muciniphila and Product and Application Thereof | March 2024 | December 2025 | Allow | 21 | 5 | 0 | Yes | No |
| 18401511 | RECOMBINANT ZYMOMONAS MOBILIS FOR PRODUCING ETHYLENE GLYCOL, METHOD AND USES THEREOF | December 2023 | July 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18323983 | METHOD FOR PREPARING MULTISUBUNIT SCF E3 LIGASE WITH FUSION PROTEIN THROUGH IN VITRO RECONSTITUTION, AND USE OF MULTISUBUNIT SCF E3 LIGASE | May 2023 | May 2025 | Allow | 24 | 2 | 0 | Yes | No |
| 18318531 | METHOD FOR ALLEVIATING OSTEOARTHRITIS | May 2023 | March 2026 | Allow | 34 | 1 | 0 | No | No |
| 18313150 | PIPELINE FOR SMALL MOLECULE DISCOVERY | May 2023 | September 2025 | Abandon | 28 | 2 | 0 | No | No |
| 18313154 | INTEGRATION OF RENEWABLE CHEMICAL PRODUCTION INTO OIL, GAS, PETROLEUM, AND CHEMICAL PROCESSING AND INFRASTRUCTURE | May 2023 | January 2026 | Abandon | 33 | 4 | 1 | No | No |
| 18148112 | PARA-AMINOBENZOIC ACID-PRODUCING MICROORGANISM | December 2022 | February 2026 | Abandon | 38 | 3 | 0 | Yes | No |
| 18011455 | METHOD FOR SYNTHESIZING BETA-NICOTINAMIDE MONONUCLEOTIDE AND INTERMEDIATE THEREOF | December 2022 | February 2026 | Allow | 38 | 1 | 0 | Yes | No |
| 17990494 | METHODS OF INFUSING FOREIGN COMPOUNDS INTO FUNGUS ORGANISMS | November 2022 | May 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18046695 | GENETICALLY ENGINEERED RHODOPSEUDOMONAS PALUSTRIS | October 2022 | February 2025 | Abandon | 28 | 2 | 0 | No | No |
| 17757463 | PRESERVATION OF NUCLEIC ACID SEQUENCES BY FIXING TISSUES IN BUFFERED FORMALIN PREPARED WITH ACID-DEPRIVED FORMALDEHYDE | June 2022 | December 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17779909 | NOVEL MODIFIED POLYPEPTIDE WITH ATTENUATED ACTIVITY OF CITRATE SYNTHASE AND METHOD FOR PRODUCING L-AMINO ACID USING THE SAME | May 2022 | September 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17776900 | BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS | May 2022 | August 2024 | Allow | 27 | 0 | 0 | Yes | No |
| 17698539 | METHOD AND DEVICE FOR FORMING A GEL PARTICLE SLURRY | March 2022 | May 2025 | Abandon | 38 | 4 | 0 | No | No |
| 17642928 | SYSTEMS AND METHODS FOR IN-VITRO MODELING OF NEURODEGENERATIVE DISEASES | March 2022 | October 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17627289 | COMPOSITIONS AND METHODS FOR BROILER HEALTH AND PERFORMANCE | January 2022 | November 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17625136 | ENGINEERED ALPHA-1,3 BRANCHING ENZYMES | January 2022 | March 2026 | Allow | 50 | 2 | 1 | No | No |
| 17563271 | STABLE CORONAVIRUS PROTEINS AND VACCINE COMPOSITIONS THEREOF | December 2021 | June 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17597064 | LACTOBACILLUS DELBRUECKII SUBSP. LACTIS LDL557, AND COMPOSITION AND USE THEREOF | December 2021 | September 2025 | Allow | 45 | 2 | 0 | No | No |
| 17554659 | PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME | December 2021 | October 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17619393 | OXIDASE-BASED CHEMILUMINESCENCE ASSAY OF PHAGOCYTIC LEUKOCYTES IN WHOLE BLOOD AND BODY FLUIDS APPLICABLE TO POINT-OF-CARE (POC) DIAGNOSTIC TESTING POINT-OF-CARE (POC) MEASUREMENT OF ABSOLUTE NEUTROPHIL FUNCTION (ANF) | December 2021 | March 2026 | Abandon | 51 | 2 | 1 | No | No |
| 17613315 | ENZYMATIC PRODUCTION OF FRUCTOSE | November 2021 | February 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17609138 | METHODS FOR IMPROVING TREATMENT OF EQUINE COLIC BY ADMINISTRATION OF A SYNTHETIC BIOENSEMBLE OR PURIFIED STRAINS THEREOF | November 2021 | January 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17609190 | EXOSOME COMPRISING STABILIZED RNA THERAPEUTICS | November 2021 | December 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17311131 | REAGENT FOR MEASURING FIBRINOGEN | October 2021 | October 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17605391 | COMPOSITION COMPRISING LACTOBACILLUS REUTERI ATG-F4 FOR PREVENTION OR TREATMENT OF MUSCULAR DISORDER | October 2021 | September 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17604412 | PHOSPHINOTHRICIN DEHYDROGENASE MUTANT, GENETICALLY ENGINEERED BACTERIUM AND ONE-POT MULTI-ENZYME SYNCHRONOUS DIRECTED EVOLUTION METHOD | October 2021 | July 2024 | Allow | 33 | 0 | 1 | Yes | No |
| 17450802 | FLEXIBLE PRODUCT SEPARATION AND RECOVERY | October 2021 | February 2026 | Abandon | 52 | 3 | 1 | No | No |
| 17602676 | COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES | October 2021 | March 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17600319 | METHOD OF INTRODUCING TARGET-SPECIFIC FOREIGN GENE | September 2021 | March 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17599500 | COMPOSITION FOR PREVENTING OR TREATING NEUROINFLAMMATORY DISORDERS, COMPRISING BEE VENOM EXTRACT AS ACTIVE INGREDIENT | September 2021 | January 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17598408 | A METHOD FOR THE PREPARATION OF FREEZE-DRIED QUALITY CONTROL PELLETS OF ESCHERICHIA COLI | September 2021 | November 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17485680 | Fusion Peptide for Forming Virus-Like Particle | September 2021 | March 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17440300 | MICROBIAL STRAINS FOR VIRUS INHIBITION | September 2021 | March 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17435670 | MULTI-LACTOBACILLUS COMPOSITION AND APPLICATION THEREOF TO VAGINAL HEALTH OF FEMALES | September 2021 | November 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17435146 | METHOD FOR PRODUCING OXYGEN ADDUCT OF SESQUITERPENE,COMPOUND AND COMPOSITION | August 2021 | November 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17310779 | EQUAL ENERGY DEFORMATION COMPOSITE FOUNDATION USING MICROORGANISMS TO SOLIDIFY AGGREGATE AND THE CONSTRUCTION METHOD THEREOF | August 2021 | August 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17407106 | HYDROPHOBIC INTERACTION CHROMATOGRAPHY CARRIER AND PROTEIN PURIFICATION METHOD | August 2021 | January 2026 | Allow | 53 | 3 | 0 | Yes | No |
| 17429555 | LACTIC ACID BACTERIUM WITH A REDUCTION OF SENSITIVITY TO COS-TYPE BACTERIOPHAGES | August 2021 | November 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17429162 | Temperature optimized L-arabinose isomerase mutants | August 2021 | October 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17358163 | MICROBIOLOGICAL PRODUCTION OF SHORT FATTY ACIDS AND USES THEREOF | June 2021 | July 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17415640 | CELL-FREE PRODUCTION OF ALLULOSE | June 2021 | May 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17312869 | WEISSELLA BACTERIA-DERIVED NANOVESICLE AND USE THEREOF | June 2021 | December 2024 | Abandon | 42 | 4 | 0 | No | No |
| 17329783 | PROCESSING PROTEIN | May 2021 | March 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17295959 | SUBTILISIN VARIANTS HAVING IMPROVED STABILITY | May 2021 | September 2025 | Allow | 52 | 1 | 1 | Yes | No |
| 17324985 | METHOD FOR SEEDING CELLS ON A SENSOR SURFACE | May 2021 | May 2025 | Abandon | 48 | 2 | 1 | Yes | No |
| 17286636 | NEW MUTANT PROTEIN FOR IMPROVING MALIC ACID YIELD | April 2021 | May 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17270358 | DEGRADATION DOMAIN MODIFICATIONS FOR SPATIO-TEMPORAL CONTROL OF RNA-GUIDED NUCLEASES | February 2021 | December 2025 | Abandon | 58 | 3 | 1 | Yes | No |
| 17269123 | FUSION PROTEINS FOR HYDROXYLATING AMINO ACIDS AND PRODUCTS | February 2021 | January 2025 | Allow | 47 | 2 | 1 | No | No |
| 17178091 | METHODS AND SYSTEMS FOR PREPARING THERAPEUTIC SOLUTIONS FOR POLYMICROBIAL INFECTIONS | February 2021 | February 2026 | Abandon | 60 | 4 | 0 | No | No |
| 17263420 | BIO-CELLULOSE SHEET AND PREPARATION METHOD THEREOF | January 2021 | June 2024 | Abandon | 41 | 1 | 0 | No | No |
| 15733936 | COMPOSITIONS AND METHODS TO PROMOTE HOST DEFENSE AND STIMULATE, EXPAND, AND/OR RESET T CELL REPERTOIRES | December 2020 | October 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17030306 | METHOD FOR REMOVING N-TERMINAL TRUNCATED AND ABNORMAL VARIANTS IN RHNGF | September 2020 | April 2024 | Abandon | 43 | 1 | 0 | No | No |
| 16921799 | SILK FIBERS | July 2020 | May 2024 | Abandon | 46 | 0 | 1 | No | No |
| 16329759 | LEUCONOSTOC HOLZAPFELII STRAIN FOR PREVENTING DEPILATION IMPROVING HAIR GROWTH OR IMPROVING SEXUAL DISFUNTION AND COMPOSITION COMPRISING THE SAME | February 2019 | November 2024 | Abandon | 60 | 1 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner SPANGLER, JOSEPH RANKIN works in Art Unit 1656 and has examined 38 patent applications in our dataset. With an allowance rate of 34.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner SPANGLER, JOSEPH RANKIN's allowance rate of 34.2% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SPANGLER, JOSEPH RANKIN receive 1.39 office actions before reaching final disposition. This places the examiner in the 22% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SPANGLER, JOSEPH RANKIN is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +76.6% benefit to allowance rate for applications examined by SPANGLER, JOSEPH RANKIN. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 22.2% are granted (fully or in part). This grant rate is in the 11% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.